Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ROR1)

US12268741B2 · kind B2 · utility

Assignee

• Juno Therapeutics, Inc. · US

Inventors

• Andreia COSTA · Seattle, US
• Rupesh Amin · Seattle, US
• Jenna BAILEY · Seattle, US
• Samriti BEDI · Newcastle, US
• Brian J. Belmont · Cambridge, US
• Aye CHEN · Seattle, US
• Stephen J. Goldfless · Seattle, US
• Eric W. Jeffery · Seattle, US
• Yue JIANG · Seattle, US
• Yeonjoo OH · Seattle, US
• Madeline WILLIAMS · Seattle, US
• Collin HAUSKINS · Seattle, US
• Catherine SIERRA · Seattle, US

Key dates

• Filing date: Jan 28, 2020
• Grant date: Apr 8, 2025
• Expiry date: Nov 26, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/74
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided are receptor tyrosine kinase-like orphan receptor 1 (ROR1)-binding molecules, in particular, to human antibodies specific for ROR1, including antibody fragments. The present disclosure further relates to recombinant receptors, including chimeric antigen receptors (CARs) that contain such antibodies or fragments, and polynucleotides that encode the antibodies, antigen-binding fragments or receptors specific for ROR1. The disclosure further relates to genetically engineered cells, containing such ROR1-binding proteins and receptors, and related methods and uses thereof in adoptive cell therapy.